Day: January 26, 2021

Company AnnouncementNet sales of DARZALEX® in 2020 totaled USD 4,190 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc.Copenhagen, Denmark; January 26, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous formulation (sold under the tradename DARZALEX FASPRO®  in the U.S.), as reported by Johnson & Johnson were USD 4,190 million in 2020. Net trade sales were USD 2,232 million in the U.S. and USD 1,958 million in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX FASPRO under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize daratumumab. As previously announced, Janssen is reducing its royalty payments to Genmab...

NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI; the “Company”) plans to announce its financial results for the fourth quarter and full year 2020 after the closing of the New York Stock Exchange on Thursday, February 25, 2021. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company’s website, www.ftandi.com.In addition, management will host a conference call on Friday, February 26, 2021 at 8:00 A.M. Eastern Time. The conference call may be accessed by dialing (877) 447-5636 (from within the U.S.) or (615) 247-0080 (from outside of the U.S.) ten minutes prior to the scheduled start of the call; please reference “FTAI Fourth Quarter 2020 Earnings Call.”A simultaneous webcast of...

84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one yearBone mineral density loss was minimal at Week 24 and remained stable through one yearData to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021BASEL, Switzerland and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis...

EDMONTON, Alberta, Jan. 26, 2021 (GLOBE NEWSWIRE) — TSX,NYSE: STNStantec will release its fourth quarter and full-year 2020 financial results after markets close on Wednesday, February 24, 2021. On Thursday, February 25, 2021, at 7:00 AM Mountain Time (9:00 AM Eastern Time), Gord Johnston, President and Chief Executive Officer, and Theresa Jang, Executive Vice President and Chief Financial Officer, will hold a conference call to discuss the Company’s performance.The webcast and slide presentation can be accessed at the following link:https://edge.media-server.com/mmc/p/whiotnb8The conference call and slideshow presentation will be broadcast live and archived in their entirety in the Investors section of stantec.com. Participants wishing to listen to the call via telephone may dial in toll-free at 1-866-548-4713 (Canada and United...

DAYTONA BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) — TopBuild Corp. (NYSE:BLD), a leading installer and distributor of insulation and building material products in the United States, will release its fourth quarter and year-end 2020 results prior to 7:00 a.m. on Tuesday, February 23. The Company will host a conference call at 9:00 a.m. Eastern time that same day to review its financial results.Live Call: US/Canada callers dial (877) 407-9037A live, listen-only webcast can be accessed through the Company’s Web site at www.topbuild.com under the “Investor Relations” section. A replay of the call will also be available on the Company’s web site.About TopBuildTopBuild Corp., a Fortune 1000 Company headquartered in Daytona Beach, Florida, is a leading installer and distributor of insulation and building material products to the U.S....

TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live demonstration, during the Leipzig Interventional Congress being held virtually from January 25-29, 2021.Highlights include:Wednesday, January 27, 2021, “Innovative Concepts in Carotid Revascularization”“12-month results from a prospective real world multicenter clinical practice of CAD using the CGuard Embolic Prevention system: the IRONGUARD 2 study.” Author: Pasqualino Sirignano, M.D., Vascular and Endovascular Surgery Division, Department of Surgery “Paride Stefanini,” Policlinico Umberto I “Sapienza,” University of Rome.“Carotid artery revascularization:...

Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer:Median overall survival of 12.5 months in patients with moderately-well differentiated tumors despite an average of 7 failed prior therapy regimens (versus 7.2-9.8 months of others).Prolonged survival rates and highest tumor reductions were observed in specific patients identifiable through two different bio-marker techniques: tumor type and HLA types.BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce...

紐約州水牛城, Jan. 26, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX) 是致力研究、開發和商業化治療癌症和相關疾病新療法的全球生物製藥公司，今天宣佈其行政總裁兼董事會主席 Johnson Lau 博士已出院並於家中休養。他繼續履行 Athenex 行政總裁及主席的全部責任及職責。關於 Athenex, Inc.Athenex, Inc. 創建於 2003 年，是一家臨床階段的國際生物製藥公司，並致力成為研究、開發及商業化下一代癌症治療藥物的領導者。Athenex 下設三個平台，分別為腫瘤創新平台、商業平台及全球供應鏈平台。公司現有的臨床產品系列源自四個不同平台的科技：(1) 以 p-糖蛋白抑制劑為基礎的 Orascovery；(2) Src 酶抑制劑；(3) 受體工程化 T 細胞 (TCR-T) 及 (4) 精氨酸消除療法。Athenex 的員工遍佈全球，致力透過開發更有效及耐受的治療來改善癌症病人的生活。Athenex 在紐約水牛城和克拉倫斯、新澤西州克蘭福德、德克薩斯州休斯頓、伊利諾伊州芝加哥、香港、台灣台北、中國重慶多個地方、英國曼徹斯特、危地馬拉的危地馬拉城和阿根廷布宜諾斯艾利斯設有辦事處。如欲了解更多資訊，請瀏覽 www.athenex.com。前瞻性聲明除了歷史上的資訊，所有在新聞稿中的陳述、期望和假設均為前瞻性陳述。這些前瞻性陳述通常通過諸如「預料」、「相信」、「繼續」、「將能」、「估計」、「預期」、「預見」、「目標」、「指導」、「打算」、「可能」、「可會」、「計劃」、「潛力」、「預計」、「初步」、「或許」、「預測」、「可為」、「尋求」、「應該」、「將」、「會」和類似的用詞作表達。實際結果可能與前瞻性陳述中明確或隱含的結果不同。可能導致實際結果出現重大差異的重要因素包括：我們主要臨床候選藥物的發展階段以及藥物開發、臨床試驗、監管、製造和商業化中涉及的相關風險；我們依賴第三方在...